ArticleThe Pan African medical journal2022
Risk factors for mortality among multi-drug resistant tuberculosis patients in treatment follow-up centers, eastern Ethiopia: a retrospective follow-up study.
Article in The Pan African medical journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: multi-drug resistance tuberculosis (MDR-TB) is associated with an increased risk of mortality among patients on treatment. Ethiopia is the countries with the high MDR-TB burden. This study aimed to determine the extent of mortality and associated factors among MDR-TB patients on treatment in eastern Ethiopia. Methods: all completely documented data from June 2014 to January 2017 on MDR-TB patients were extracted from patients´ records, between December 2016 and January 2017, in Dader and Dire Dawa MDR treatment follow-up centers. Sociodemographic characteristics, clinical characteristics of MDR-TB patients, and treatment outcomes were extracted from the patients' records. Descriptive statistical methods were used to characterize the sociodemographic variables and the extent of mortality. Binary and multivariable logistic regression analyses were performed to assess factors associated with mortality using an adjusted odds ratio (AOR) at 95% confidence interval (CI). Statistical significance was considered at a P-value of less than 0.05. Results: among 150 MDR-TB patients, 60.7% of them were males and their mean age was 30.34 + 1.06 years. In this study, the overall mortality rate was 11.3% (95% CI= 6.74-17.52). Previous history of ant-TB treatment (AOR=6.7, 95% CI: 1.59 - 17.15, P= 0.019), hospitalization (AOR=19.55, 95% CI: 6.23-43.37, P=0.001), and human immunodeficiency virus (HIV) coinfection (AOR=6.3, 95% CI: 2.98- 14.0, P= 0.008) were significantly associated with this mortality. Conclusion: considerably high rate of mortality among MDR-TB patients on treatment highlights the need for more efforts in TB treatment and monitoring the program to limit mortality among MDR-TB patients in the study settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.